BrightPath to Present Updates on the Preclinical Data of BP2301,BP1200,BP1209 at AACR 2022

BrightPath Biotherapeutics (TSE Mothers 4954), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that preclinical data on BP2301(HER2 CAR-T), BP1200(anti-CD73 antibody) and BP1209(Personalized neoantigen vaccine) will be presented at the American Association for Cancer Research Annual Meeting ("AACR 2022") on April 8-13. The poster presentations will be posted on the website of BrightPath after AACR 2022 is held.

■BP2301
Abstract Title: Development of piggyBac transposon-mediated HER2-CAR-T cells for the treatment of solid tumors
Date & Time: 0 p.m.-1 p.m. CST on Friday, April 8, 2022
Poster Session: Preclinical Immunotherapy
Abstract number: 5570
https://www.abstractsonline.com/pp8/#!/10517/presentation/18679

■BP1209_1
Abstract Title: A novel computational pipeline supported with in vivo T cell induction data for identification and validation of neoantigens
Date & Time: 0 p.m.-1 p.m. CST on Friday, April 8, 2022
Poster Session: Computational Frameworks and Resources
Abstract number: 6389
https://www.abstractsonline.com/pp8/#!/10517/presentation/21653

■BP1200
Abstract Title: A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
Date & Time: 9 a.m.-0:30 p.m. CST on Tuesday, April 12, 2022
Poster Session: Therapeutic Antibodies 2
Abstract number: 2905/20
https://www.abstractsonline.com/pp8/#!/10517/presentation/16939

■BP1209_2
Abstract Title: Personalized neoantigen cancer vaccine assembled on DC targeting antibody improves cancer immunity
Date & Time: 1:30 p.m.-5 p.m. CST on Tuesday, April 12, 2022
Poster Session: Vaccines: Oncolytic and Prophylactic
Abstract number: 3552/2
https://www.abstractsonline.com/pp8/#!/10517/presentation/16976